Silence Therapeutics plc Stock London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 587M 800M 685M 642M 1.11B 76.24B 1.12B 7.57B 2.95B 38.46B 3B 2.94B 127B | P/E 2026 * |
-19.7x | P/E 2027 * | -16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 453M 618M 530M 496M 856M 58.94B 864M 5.86B 2.28B 29.74B 2.32B 2.27B 98.47B | EV / Sales 2026 * |
1,396x | EV / Sales 2027 * | 550x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-11-30 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-01-31 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2003-12-31 |
Tim McInerney
BRD | Director/Board Member | 65 | 2025-05-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.02% | +4.84% | +4.80% | +24.36% | 51.21B | |
| -0.09% | -2.14% | +492.60% | +537.84% | 45.35B | |
| -0.32% | +8.08% | +37.97% | +18.45% | 42.84B | |
| +1.18% | +1.96% | +21.95% | +89.69% | 42.29B | |
| -2.27% | -5.67% | +14.55% | +50.34% | 32.15B | |
| -0.96% | +4.03% | +31.55% | +136.34% | 17.31B | |
| +0.41% | +1.66% | - | - | 16.55B | |
| +1.12% | +5.83% | +8.37% | +32.33% | 14.84B | |
| -0.31% | +6.61% | +81.37% | +48.53% | 14.25B | |
| Average | +0.00% | +3.06% | +86.64% | +117.24% | 30.75B | |
| Weighted average by Cap. | +0.10% | +2.89% | +105.43% | +135.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 325K 443K 379K 356K 613K 42.21M 619K 4.19M 1.63M 21.3M 1.66M 1.63M 70.53M | 751K 1.02M 877K 822K 1.42M 97.56M 1.43M 9.69M 3.77M 49.22M 3.84M 3.76M 163M |
| Net income | -41.45M -56.51M -48.43M -45.38M -78.22M -5.39B -79M -535M -208M -2.72B -212M -208M -9B | -66.28M -90.37M -77.44M -72.56M -125M -8.62B -126M -856M -333M -4.35B -339M -332M -14.4B |
| Net Debt | -133M -181M -155M -146M -251M -17.3B -254M -1.72B -669M -8.73B -681M -667M -28.91B | -174M -237M -203M -191M -328M -22.62B -332M -2.25B -875M -11.41B -891M -872M -37.8B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
